ONC vs RCUS

For growth investors, BeOne Medicines Ltd.

(ONC) is the stronger pick with 40. 2% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). BeOne Medicines Ltd. (ONC) offers the better valuation at 9. 6x trailing P/E (51. 9x forward), making it the more compelling value choice. Analysts rate BeOne Medicines Ltd. (ONC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, BeOne Medicines Ltd.

(ONC) delivered a total return of +1. 6%, compared to -18. 6% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: ONC returned +1046% versus RCUS's +45. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BeOne Medicines Ltd.

(ONC) is the lower-risk stock at 0. 70β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 180% more volatile than ONC relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 46% for BeOne Medicines Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BeOne Medicines Ltd.

(ONC) is pulling ahead at 40. 2% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: BeOne Medicines Ltd. grew EPS 637. 4% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, ONC leads at 55. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BeOne Medicines Ltd.

(ONC) is the more profitable company, earning 5. 4% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 5. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ONC leads at 8. 4% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ONC: 26.

6% to $401. 29.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BeOne Medicines Ltd.

(ONC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 70), +1046% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ONC: +1046%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ONC is a mid-cap high-growth stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.